| Previous Close | 317.93 |
| Open | 318.61 |
| Bid | 279.26 x 100 |
| Ask | 400.00 x 100 |
| Day's Range | 316.52 - 321.60 |
| 52 Week Range | 244.28 - 330.00 |
| Volume | 849,480 |
| Avg. Volume | 1,360,978 |
| Market Cap | 67.45B |
| Beta | 0.50 |
| PE Ratio (TTM) | 20.93 |
| EPS (TTM) | 15.24 |
| Earnings Date | Oct 24, 2017 - Oct 30, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 333.02 |
- Benzinga•14 hours ago
Biogen Spinoff Bioverativ Is A Buy
Analysts at Argus Research turned bullish on Bioverativ Inc (NASDAQ: BIVV ) as the company could establish itself as a profitable biotech within the hemophilia and blood disorders space. The firm's Jasper ...
Markit•16 hours agoSee what the IHS Markit Score report has to say about Biogen Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $1.03 billion.
- InvestorPlace•2 days ago
Profit From the Biogen Inc (BIIB) Stock Dip!
Biogen Inc (NASDAQ:BIIB) stock had a fantastic start to September with a 15% rally. Clearly, this is a momentum stock, so it will never give us a clear signal for entry. More often than not, traders tend to overshoot with the price action of momentum stocks.
